Dow Up0.11% Nasdaq Up0.50%

More On SKP.L

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


SkyePharma plc (SKP.L)

-LSE
306.00 0.00(0.00%) Aug 29, 11:36AM EDT
ProfileGet Profile for:
SkyePharma plc
46-48 Grosvenor Gardens
London, SW1W 0EB
United Kingdom - Map
Phone: 44 20 7881 0524
Fax: 44 20 7881 1199
Website: http://www.skyepharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:79

Business Summary 

Skyepharma PLC, an oral and inhalation drug delivery company, develops, manufactures, and sells oral and inhalation pharmaceutical products. Its marketed products include flutiform and ZYFLO CR for treating asthma; Relvar Ellipta/Breo Ellipta for asthma and COPD; Anoro Ellipta for COPD; Paxil CR for depression treatment; Requip Once-a-day and Madopar DR to treat Parkinson’s disease; Triglide for treating lipid disorders; Sular to treat hypertension; Diclofenac-ratiopharm-uno for pain/inflammation; and Lodotra/Rayos to treat rheumatoid arthritis. The company’s marketed products also comprise Coruno to treat angina; Xatral OD/Uroxatral for treating BPH (urinary symptoms); Solaraze for actinic keratosis treatment; and EXPAREL, which is used for pain management. Its development pipeline includes SKP-1041, which has completed Phase II clinical trails for sleep maintenance; and SKP-1052, which has completed Phase I clinical trails for use in reducing the risk of nocturnal hypoglycaemia in insulintreated patients. The company also owns a novel inhaled therapy platform. It markets its products through specialty pharmaceutical companies worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

Key Statistics


Company Websites 
Home Page
Investor Relations
Employment
Search Yahoo! for:
More on SkyePharma plc

Key Executives 
 PayExercised
Mr. Peter William Grant , 58
Chief Exec. Officer and Exec. Director
642.00KN/A
Mr. Andrew Derodra , 48
Chief Financial Officer and Exec. Director
79.00KN/A
Mr. John Murphy , 61
Gen. Counsel and Company Sec.
N/AN/A
Dr. Geraldine Venthoye ,
Exec. VP of Pharmaceutical Devel.
N/AN/A
Dr. Guy Vergnault ,
Exec. VP of Oral Drug Delivery Solutions
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in GBp.